Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

TCR2 Therapeutics

Main focus: Next-generation iPSC-derived cell therapies

Company stage: Clinical

Diseases (gene editing): Solid tumours, haematological cancers

Genome editing tool: CRISPR

Funding stage: Public (NASDAQ:TCRR)

Location: Cambridge, MA, USA

Website: https://www.tcr2.com/

Pipeline: https://www.tcr2.com/our-pipeline/

Gene editing partnerships: Arbor Biotechnologies

TCR2 Therapeutics is developing next-generation cellular therapies to treat cancer. The company's technology is based on TCR Fusion Construct (TRuC) T cells that are engineered to recognise tumour cells. The company's engagement in the gene-editing space comes through its collaboration with Arbor Biotechnologies, giving TCR2 access to CRISPR-based gene-editing systems for the development of allogeneic cell therapies.

Tags

HashtagTCR2 Therapeutics

Company: TCR2 Therapeutics
close
Search CRISPR Medicine